COMPOUNDS AND METHODS FOR USING Russian patent published in 2015 - IPC C07D417/14 C07D487/04 A61K31/538 A61K31/4709 A61P7/02 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound or its pharmaceutically acceptable salt; the compound is a) described by Formula wherein R¹ is absent; the index n means an integer from 0 to 2; when n = 0, then X¹ means -CH₂-; X¹ means a member specified in a group consisting of -CH₂-, -O-, -N(H)- and -N(R^a)-, wherein R^a is specified in a group consisting of C_1-6alkyl; each X^2a, X^2b and X^2c is independently specified in a group consisting of C(H); A means a member specified in a group and (aa), wherein R³ is independently specified in a group consisting of halogen and -R^g, wherein R^g is specified in a group consisting of C_1-4alkyl; B means a member specified in a group of compounds and (aaa), wherein R^4a is absent; L is absent or means a member specified in a group consisting of C₆arylene-C_1-6heteroalkylene, C_1-6heteroalkylene, C_1-6alkylene, C_2-6alkenylene, C_2-6alkynylene and -O-; heteroalkylene contains 1 or 2 heteroatoms specified in a group consisting of N, O or S; E means hydrogen or halogen; or alternatively, E is specified in a group consisting of phenyl, C_5-6heteroaryl; C_5-6heteroaryl is specified in a group consisting of pyrazol, pyridine and pyrazine, C_3-7heterocycloalkyl; C_3-7heterocycloalkyl is specified in a group consisting of morpholine, pyrrolidine, piperidine and piperazine, and C_3-7cycloalkyl, and if so required 1 ring independently specified in a group consisting of a 5-merous heterocyclic ring containing 2 O heteroatoms, a benzene ring and a 5,6-merous heteroaromatic ring containing 2 N heteroatoms can be condensed with E; E and 1 ring condensed with E if so required are independently protected 0 to 5 times by substitutes R⁶ specified in a group consisting of halogen, -NR^pR^q, -OR^p, -C(O)OR^p, -NR^pC(O)OR^r, -S(O)₂R^r, -R^r, -R^s, =O, -Z¹-NR^pR^q and -Z^1-R^s; Z¹ means C_1-6alkylene; each R^p and Rq are independently specified in hydrogen and C_1-6alkyl; R^r is specified in a group consisting of C_1-6alkyl and phenyl; R^s is specified in a group consisting of phenyl and pyrazole, and 1 pyrimidine ring can be condensed with R^s. Or the compound b) is specified in a group consisting of 2-(1-(benzo[d]thiazol-2-ylcarbamoyl)-1,2,3,4-tetrahydroquinolin-7-yl)-5-(4-methoxyphenyl)-N,N-dimethylthiazol-4-carboxamide, 2-(1-(benzo[d]thiazol-2-ylcarbamoyl)-1,2,3,4-tetrahydroquinolin-7-yl)-5-(4-fluorophenoxy)thiazol-4-carboxamide and N-(benzo[d]thiazol-2-yl)-6-(6-(methylsulphonylcarbamoyl)-5-(3-phenoxypropoxy)pyridin-2-yl)-2H-benzo[b][1,4]oxazine-4(3H)-carboxamide. The invention also refers to specific compounds. The compounds according to the inventions are applicable for a pharmaceutical composition having BCl-X_L antiapoptosis protein inhibitory activity. The pharmaceutical composition contains a therapeutically effective amount of the composition of formula a) or b), or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable diluent, carrier or excipient.

EFFECT: new compounds inhibiting BCl-X_L antiapoptosis protein.

21 cl, 2 tbl, 7 dwg, 66 ex